Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $1.0 million.

  • Celldex Therapeutics' Amortizatization of Intangibles fell 7650.59% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 4276.69%. This contributed to the annual value of $15.7 million for FY2024, which is 15311.8% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Amortizatization of Intangibles stood at $1.0 million, which was down 7650.59% from $1.7 million recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Amortizatization of Intangibles high stood at $4.7 million for Q2 2024, and its period low was -$772000.0 during Q1 2022.
  • In the last 5 years, Celldex Therapeutics' Amortizatization of Intangibles had a median value of $1.3 million in 2023 and averaged $1.5 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Amortizatization of Intangibles skyrocketed by 361724.14% in 2021, and later tumbled by 170833.33% in 2022.
  • Celldex Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$198000.0 in 2021, then surged by 363.64% to $522000.0 in 2022, then skyrocketed by 317.43% to $2.2 million in 2023, then soared by 54.34% to $3.4 million in 2024, then plummeted by 69.73% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.7 million for Q2 2025, and $2.3 million during Q1 2025.